HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Clinical trials for HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for aggressive breast cancer
Disease control CompletedThis study tested two treatment plans for people with advanced HR-positive, HER2-negative breast cancer that is aggressive. One group received a drug called abemaciclib plus hormone therapy. The other group started with a short course of chemotherapy, then switched to abemaciclib…
Matched conditions: HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Real-World data reveals how breast cancer patients fare after initial therapy
Knowledge-focused CompletedThis completed study analyzed data from 1,415 patients with HR-positive, HER2-negative metastatic breast cancer in the United States. Researchers looked at what happened after patients progressed on their first-line treatment (endocrine therapy plus a CDK4/6 inhibitor) and starte…
Matched conditions: HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER
Sponsor: Daiichi Sankyo • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC